An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.

Trial Profile

An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Biomarker; Diagnostic use
  • Acronyms EVOLUTION
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 5 Sep 2017.
    • 12 Jun 2017 Planned End Date changed from 2 Oct 2017 to 1 Sep 2017.
    • 12 Jun 2017 Planned primary completion date changed from 24 Jul 2017 to 25 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top